What Are Peptides?
Peptides are short chains of amino acids, the building blocks of proteins. Here's everything you need to know.
The Basics
Peptides are molecules made up of 2 to 50 amino acids linked together in a chain. They are smaller than proteins (which are longer chains) but work in a similar way, binding to receptors and triggering specific biological responses.
Your body naturally produces hundreds of peptides to regulate everything from hunger and metabolism to sleep, mood, tissue repair, and hormone release. Synthetic peptides mimic or enhance these natural signals.
Unlike anabolic steroids, most peptides work by stimulating your body's own production of hormones or natural repair processes, rather than replacing them directly.
How Peptides Work
Receptor Binding: Peptides bind to specific receptors on cell surfaces, like a key in a lock. Each peptide targets a specific receptor type, causing a precise biological effect.
Signaling Cascades: Once a peptide binds to its receptor, it triggers a cascade of cellular signals. For example, GLP-1 agonists signal the brain to suppress appetite and signal the pancreas to release insulin.
Targeted Effects: Because peptides work through specific receptors, they tend to have targeted effects with fewer systemic side effects than many traditional medications.
Peptide Categories
Weight Loss (GLP-1 Agonists)
| Peptide | Receptors | Avg Weight Loss | Approval status |
|---|---|---|---|
| Tirzepatide | GLP-1, GIP (2) | 22.5% | Approved by the FDA for weight management, as Zepbound, NDA 2178065 |
| Semaglutide | GLP-1 (1) | 15% | Approved by the FDA for weight management, as Wegovy, NDA 2152564 |
This is a map of what is studied for each purpose, not a recommendation; what suits a person is a prescriber's decision. Published trial figures, not a guaranteed result for an individual, and the two come from separate trials, so they do not compare directly.
Retatrutide is deliberately not a row in this table. It is an investigational compound, not an approved medicine. Parts of its phase 3 program were still listed on ClinicalTrials.gov as recruiting or active when this page was checked on 5 September 2026: several of its pivotal phase 3 trials were still ongoing at that date, and no regulator had listed an approval for it, in Vietnam or anywhere else.7 The figure usually quoted for it comes from a 48 week phase 2 trial in 338 adults, in which 12 mg once weekly gave a least squares mean body weight change of 24.2 percent (trial dose, not a recommendation, PMID 37366315).6
Healing & Recovery
Growth Hormone
Anti-Aging & Longevity
Nootropics & Mood
The categories above describe what each compound is studied for, with the evidence level stated on its profile page; they are not a recommendation, and what suits a person is a prescriber's decision.
Peptides commonly studied for each goal
The table below lists the compounds that appear most often in the research literature for each direction, with the evidence level each one carries on its own profile page on this site. This is a map of what is studied for each purpose, not a recommendation; what suits a person is a prescriber's decision. Retatrutide is not in the table for the reason set out under the weight loss table above: it is investigational and still in phase 3.7
Evidence levels are the ones each compound's own profile page on this site carries. They describe how far the research has gone, not an approved indication in Vietnam and not a proven effect.
Are peptides legal in Vietnam?
In short, it is unsettled rather than a clear yes or no. Vietnamese law lets only registered drugs be traded and prohibits trading in drugs not yet permitted for circulation, but its rules are aimed at pharmaceutical business, not at an individual holding a small quantity for personal use, and that silence is what leaves the area gray.
Research peptides sit in a regulatory gray area in Vietnam, and this page does not settle it. The statute itself is not gray, so start there. Vietnam's Law on Pharmacy, No. 105/2016/QH13, provides that drugs shall be registered before circulation in Vietnam (Article 54, Clause 1), and that the drugs and drug materials permitted for circulation in the market are those which have a certificate of free sale (Article 59, Clause 1, Point a).1 That is the sense in which only registered drugs may be traded, and the law covers drug materials as well as finished drugs, which it defines as the components forming a drug (Article 2, Clause 3).1
The same law makes it a prohibited act to trade in drugs or drug materials not yet permitted for circulation, and, in the clause immediately before it, to trade in drugs or drug materials used as samples for registration, testing, scientific research or display at exhibitions or fairs (Article 6, Clause 5, Points e and dd).1 That second clause is the legal shape of why these compounds are commonly sold and labeled research use only, not for human use.
What the law does not do is set a rule for an individual holding a small quantity for personal use. Its prohibited acts are aimed at pharmaceutical business, trading, practice and advertising, and the 2016 text uses the word possession only in the sense of holding a professional qualification.1 That silence is the part which leaves the area gray. The 2016 law was later amended by Law No. 44/2024/QH15, in force from 1 July 2025, and we could not retrieve its full English text: the publisher's copy sits behind a subscriber wall and a second mirror returned HTTP 403. The article numbers above are therefore quoted from the 2016 text as published, not from the consolidated version.2
On whether any individual peptide holds a Vietnamese registration, this page does not claim to have looked one up. As the buying guide on this site sets out, they are not approved as pharmaceuticals by the Drug Administration of Vietnam, which is why there is no prescription route for them and why pharmacies do not stock them (unverified on this page). We tried to confirm that against the DAV's own registration disclosure portal on 5 September 2026: the portal responds, but its public search returned nothing to our tooling, and drugbank.vn, the drug database the Ministry of Health launched for exactly this kind of lookup, no longer resolves in DNS.3 That is a block on our side, not a finding about any compound.
Import and customs handling are not settled here either: the buying guide points to the peptide legality in Vietnam guide for those details. A gray area is not permission, regulations can change, and nothing here is legal advice.
Sources
Entries marked ° are cited from the publisher, but our checker could not retrieve the page to confirm the wording.
- 1.National Assembly of Vietnam. Law on Pharmacy No. 105/2016/QH13, official English translation (Vietnam Law and Legal Forum). Articles 2, 6, 54 and 59. Retrieved 5 September 2026 via FAOLEX, the FAO legal database.
- 2.National Assembly of Vietnam. Law No. 44/2024/QH15 amending and supplementing a number of articles of the Law on Pharmacy, passed 21 November 2024, in force 1 July 2025. Full English text not retrievable on 5 September 2026: subscriber wall at the publisher, HTTP 403 at a second mirror.°
- 3.Drug Administration of Vietnam. Cong bo giay dang ky thuoc, nguyen lieu lam thuoc tai Viet Nam, the DAV registration disclosure portal. Checked 5 September 2026: the portal responded, its public search returned no result to our tooling, and drugbank.vn did not resolve in DNS.°
- 4.U.S. Food and Drug Administration. WEGOVY (semaglutide) injection prescribing information, application NDA 215256, retrieved 5 September 2026 from the openFDA drug label API.
- 5.U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection prescribing information, application NDA 217806, Eli Lilly and Company, retrieved 5 September 2026 from the openFDA drug label API.
- 6.Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine 2023;389(6):514-526. PMID 37366315, ClinicalTrials.gov NCT04881760.
- 7.ClinicalTrials.gov. Phase 3 studies of retatrutide (LY3437943), including NCT07232719 and NCT06662383, listed recruiting or active and not completed as of 5 September 2026.